Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial

Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with ​its psoriatic arthritis treatment Taltz, improved arthritis symptoms and ‌drove weight loss better than Taltz alone.7% of patients who ‌received Taltz plus Zepbound met the main goal of the study: at least a 50% reduction in psoriatic arthritis disease activity and at least 10% weight loss after 36 weeks.